Lung Cancer Clinical Trials

• Voluntarily sign the informed consent form and comply with the protocol requirements;

• No gender restriction;

• Age: ≥18 years;

• Expected survival time ≥3 months;

• Histopathologically and/or cytologically confirmed extensive-stage small cell lung cancer that is incurable or for which there is currently no standard treatment;

• Agree to provide archived tumor tissue specimens from the primary or metastatic lesion within 3 years, or fresh tissue samples;

• Must have at least one measurable lesion as defined by RECIST v1.1;

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

• Toxicities from prior anti-tumor therapy have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0;

⁃ No severe cardiac dysfunction, with left ventricular ejection fraction (LVEF) ≥50%;

⁃ Organ function levels must meet the required criteria;

⁃ Urine protein ≤1+ or ≤1000 mg/24h;

⁃ For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the start of treatment. Serum pregnancy testing must rule out pregnancy, and the patient must not be breastfeeding. All enrolled trial participants (regardless of gender) should take adequate barrier contraceptive measures throughout the entire treatment period and for 7 months after the end of treatment.